Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly EBT Margin of 16.91% for Q2 2026, down 629.0% year-over-year from 3.2% in Q2 2025, and down 44.18% on a QoQ basis from 30.3% in Q1 2026.
Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported EBT Margin for 16 years, with the latest figure at 16.91% in Q2 2026.
- EBT Margin for Q2 2026 came in at 16.91%, down 629.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 27.87% (up 687.0% YoY), and the FY2025 annual result was 24.66%, up 403.0% from the prior year.
- EBT Margin slipped to 16.91% in Q2 2026, from 30.3% in the prior quarter.
- Over five years, EBT Margin peaked at 38.47% in Q4 2023 and troughed at 116.5% in Q2 2022.
- A 5-year average of 12.64% and a median of 24.22% in 2022 frame the typical range for EBT Margin.
- The widest annual swing landed in 2022, when EBT Margin sank 13640 bps; it then jumped 14336 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 28.62% in 2022, then soared by 34 bps to 38.47% in 2023, then sank by 33 bps to 25.9% in 2024, then grew by 15 bps to 29.72% in 2025, then tumbled by 43 bps to 16.91% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 16.91% in Q2 2026, 30.3% in Q1 2026, and 29.72% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | -0.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.91% |
| Mar 31, 2026 | 30.30% |
| Dec 31, 2025 | 29.72% |
| Sep 30, 2025 | 36.71% |
| Jun 30, 2025 | 23.20% |
| Mar 31, 2025 | 2.57% |
| Dec 31, 2024 | 25.90% |
| Sep 30, 2024 | 30.59% |
| Jun 30, 2024 | 16.71% |
| Mar 31, 2024 | 6.70% |
| Dec 31, 2023 | 38.47% |
| Sep 30, 2023 | 23.18% |
| Jun 30, 2023 | 26.86% |
| Mar 31, 2023 | -24.57% |
| Dec 31, 2022 | 28.62% |
| Sep 30, 2022 | 25.24% |
| Jun 30, 2022 | -116.50% |
| Mar 31, 2022 | 6.89% |
| Dec 31, 2021 | -4.42% |
| Sep 30, 2021 | 10.30% |